Sector News

Novartis entices UCSF director to senior position at NIBR

August 17, 2017
Life sciences

The director of UCSF’s Cardiovascular Research Institute (CRI)—Shaun Coughlin, M.D., Ph.D.—has joined the ranks of senior academics heading to drugmaker Novartis.

The MIT and Harvard-educated professor is joining Novartis, taking the role of global head of cardiovascular and metabolism at the Novartis Institutes for BioMedical Research (NIBR), the network of R&D facilities in Europe, the U.S. and China that the company describes as its “innovation engine.”

Coughlin will take up the position based at NIBR’s Cambridge, Massachusetts, campus on Nov. 1. It’s the latest in a series of appointments at Novartis that have put prominent academics in charge of R&D units at NIBR.

Former NIBR director Mark Fishman, M.D., who himself left the role of head of cardiology at Massachusetts General to head the organization for 13 years before stepping down in 2015, made hiring academic starts a feature of his tenure.

He recruited Stanford’s Ricardo Dolmetsch, Ph.D., to lead NIBR’s neuroscience activities in 2013, and two years later he brought in Dana-Farber Cancer Institute immunologist Glenn Dranoff, M.D., Ph.D., to head up its immuno-oncology efforts. That year he also recruited prominent Dana-Farber and Harvard scientist Jay Bradner, M.D., as his successor.

And the policy has continued since Bradner replaced Fishman. Last year, Novartis named Peter Hammerman, M.D., Ph.D., global head of oncology translational research and Jeff Engelman, M.D., Ph.D., as global head of oncology research, both of whom moved to the NIBR from Harvard.

Coughlin joins NIBR after more than 30 years at UCSF, serving as head of the CRI since 1997 and specializing in signaling mechanisms in cardiovascular biology and disease. He’s no stranger to the pharma industry either, having held director-level positions at Gorilla Genomics, Millennium Pharmaceuticals and COR Therapeutics.

According to an Endpoints report, the dean of UCSF Medical School, Talmadge King, M.D., said Coughlin’s research at UCSF “revealed a mechanism by which proteases regulate cellular behaviors including a key mechanism that controls blood platelet activation and clot formation. This work led to a new medical therapy for preventing heart attacks and strokes and has been honored by the American Heart Association’s Basic Science Award in 2003 and its Research Achievement Award in 2014.”

By Phil Taylor

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach